FDA Panel Advice To Limit Aquavan Administration Would Also Limit Market

If FDA takes an advisory panel's advice to limit approval of MGI Pharma's Aquavan (fospropofol) to administration only by trained anesthesiologists, the market for the sedative - which would then compete directly with its active moiety, propofol - would be substantially limited